Literature DB >> 27594272

Cause-specific mortality in women with breast cancer in situ.

Wei He1, Linda Sofie Lindström2, Per Hall1, Kamila Czene1.   

Abstract

The long-term mortality remains unknown in women diagnosed with breast cancer in situ (BCIS). Here, we assessed the cause-specific mortality in BCIS patients. This population-based cohort study included 12,243 women diagnosed with BCIS in Sweden between 1980 and 2011. Patients were followed until death, emigration, or 31 December 2013, whichever came first. The 30-year cumulative incidence of breast cancer-specific mortality was 6.3%, which is considerably lower than 49.7% observed for other-cause mortality. Women diagnosed with BCIS were more likely to die from breast cancer (standardized mortality ratio [SMR], 3.85; 95% CI, 3.47-4.27) but less likely to die from cardiovascular disease (SMR, 0.88; 95% CI, 0.82-0.95) than women in the general population. Specifically, the SMRs for breast cancer-specific mortality decreased over time from 5.19 (95% CI, 3.95-6.81) among BCIS diagnosed during 1980-1989 to 3.03 (95% CI, 2.35-3.91) among those diagnosed during 2000-2011. Furthermore, higher risk of death from other causes was seen among those with older age at BCIS diagnosis, lower levels of education, nulliparity, higher Charlson Comorbidity Index, and being hospitalized before BCIS diagnosis; whereas, lower risk of death from breast cancer was seen among BCIS diagnosed in the later time period and those with younger age at first birth. We conclude that most women diagnosed with BCIS die from causes other than breast cancer, which highlights the need for actions not only to reduce nonbreast cancer mortality but also to identify patient where extensive curative BCIS treatment is not adding to survival.
© 2016 UICC.

Entities:  

Keywords:  breast cancer in situ; cause-specific mortality; overdiagnosis and overtreatment

Mesh:

Year:  2016        PMID: 27594272     DOI: 10.1002/ijc.30413

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities.

Authors:  Jazib Gohar; Whitney L Do; Jasmine Miller-Kleinhenz; Karen Conneely; Uma Krishnamurti; Olivia D'Angelo; Keerthi Gogineni; Mylin Torres; Sheryl Gabram-Mendola; Lauren E McCullough
Journal:  Breast Cancer Res Treat       Date:  2022-01-03       Impact factor: 4.872

2.  Type of Recurrence, Cause of Death and Second Neoplasms among 737 Patients with Ductal Carcinoma In Situ of the Breast-15-Year Follow-Up.

Authors:  Anna Niwińska; Michał Kunkiel
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

3.  Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ.

Authors:  Tae-Kyung Yoo; Sang Hyun Park; Kyung Do Han; Byung Joo Chae
Journal:  BMC Cancer       Date:  2021-06-26       Impact factor: 4.430

4.  Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?

Authors:  Whitney L Do; Karen Conneely; Sheryl Gabram-Mendola; Uma Krishnamurti; Olivia D'Angelo; Jasmine Miller-Kleinhenz; Keerthi Gogineni; Mylin Torres; Lauren E McCullough
Journal:  Breast Cancer Res Treat       Date:  2020-03-31       Impact factor: 4.624

Review 5.  Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.

Authors:  Kylie L Gorringe; Stephen B Fox
Journal:  Front Oncol       Date:  2017-10-23       Impact factor: 6.244

6.  Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer.

Authors:  Vasily Giannakeas; Victoria Sopik; Steven A Narod
Journal:  JAMA Netw Open       Date:  2020-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.